In This Article
- OrganOx and its Device Metra®
- OrganOx Expands Innovation Beyond Liver Transplants
OrganOx Ltd., a leading organ medical technology company and a prominent name in organ preservation technologies, has fulfilled a goal recently and is the big news worldwide. It has completed a $142 million equity in primary and secondary finance round superheaded by HealthQuest Capital, so the growth opportunities in metra® platform technology are accelerated.
HealthQuest is supporting the existing investors of the company, BGF, and Lauxera Capital Partners, and some new investors named Sofina, Soleus Capital, and Avidity Partners to help the exponential growth of the company and to achieve its goals. Some other prominent names on the list are the University of Oxford, Technikos, the Oxford Technology and Innovations Fund, and Longwall Ventures.
OrganOx and its Device Metra®
OrganOx is the leading company working for the preservation of organs and their transplantation. Recently, it has introduced its device called metra® designed to extend the liver’s preservation time from a few hours to up to 24 hours, which is a big step toward successful liver transplantation.
The metra® is a normothermic machine perfusion system that helps to keep the liver at the body temperature and supply the required oxygenated blood, essential nutrients, and the proper medication to keep the system as normal as the body does. This is designed to keep the liver at optimal conditions and reduce the chances for liver damage. This is an innovation helping medical experts to reduce the organ discard rates.
Craig Marshall, CEO of OrganOx, shared his thoughts about this investment
With our technology, we can drastically reduce organ waste and offer better outcomes for patients in need of transplantation. This investment will help us scale our operations and expand the accessibility of our technology worldwide.
OrganOx Expands Innovation Beyond Liver Transplants
OrganOx’s metra® is approved by the U.S., Europe, Canada, and Australia and has worked in over 5000 transplants to date. The work is not just limited to liver transplants; investigations and work are being performed for kidney transplants as well, and the company is expected to start working on its trials soon.
The company has a xenotransplantation research partnership with the eGenesis, Inc. This partnership is enabling OrganOX to use metra® for genetically engineered porcine livers. This is a bold and successful alternative organ supply solutions.
The process involves in making the engineered pig liver biocompatible with humans in such a way to minimize the immune rejection rate and is a life-saving step for the patient suffering from acute-on-chronic liver failure.
The innovating technologies are helping people around the globe to live a better and healthier life therefore, Weborik Hub represents its services for AI integration in web and app solutions.
Oern R. Stuge, the MD, MBA, and Executive Chairman at OrganOx, says:
Organ disease and failure represent a large unmet need in healthcare, and we are excited to partner with HealthQuest Capital and the outstanding investor syndicate to work together to improve patient care and outcomes
Similarly, Garheng Kong, MD, PHD, and Founder/Managing Partner at HealthQuest Capital once shared his excitement:
We’re thrilled to back OrganOx as they advance a technology platform that successfully addresses the quadruple aim of healthcare, benefiting patients, healthcare providers, and global societal health in a manner that is cost-neutral to the standard of care
Collectively, the OrganOX along with its partners are working for the betterment of mankind and the investment of $142 million equity is going to boost its functions.
